Arcturus Therapeutics Holdings (ARCT) Other Operating Expenses (2024 - 2026)

Arcturus Therapeutics Holdings has reported Other Operating Expenses for 3 years, with the latest figure at -$33.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 32.68% year-over-year to -$33.0 million; the trailing twelve-month figure through Mar 2026 stood at -$244.1 million (up 36.86% YoY), and the FY2025 full-year result was -$168.8 million, up 35.76% from the prior year.
• Other Operating Expenses for Q1 2026 stood at -$33.0 million, up from -$168.8 million in the prior quarter.
• The five-year high for Other Operating Expenses was -$33.0 million in Q1 2026, with the low at -$262.7 million in Q4 2024.
• Historically, Other Operating Expenses has averaged -$105.1 million across 3 years, with a median of -$61.9 million in 2024.
• Annual changes were most pronounced in 2025 — Other Operating Expenses surged 43.45% — and 2026, when it soared 32.68%.
• Arcturus Therapeutics Holdings' Other Operating Expenses stood at -$262.7 million in 2024, then surged by 35.76% to -$168.8 million in 2025, then surged by 80.47% to -$33.0 million in 2026.
• The last three Other Operating Expenses figures came in at -$33.0 million (Q1 2026), -$168.8 million (Q4 2025), and -$42.4 million (Q2 2025), per Business Quant data.